A major evidence review has found that the HPV vaccine sharply reduces the risk of cervical cancer and carries no meaningful safety concerns. The findings, released by the nonprofit research group Cochrane, represent one of the most extensive assessments of HPV vaccination to date.
Researchers analyzed global clinical trials and real-world data representing more than 132 million individuals. Girls vaccinated at age 16 or younger had an 80% lower risk of developing cervical cancer than unvaccinated peers. The vaccine also significantly reduced high-grade precancerous lesions, particularly when given before exposure to the virus.
“These results provide clear and consistent evidence that HPV vaccination prevents cervical cancer,” said Nicholas Henschke, PhD, one of the review’s authors and head of Cochrane Response.
HPV is a common family of viruses, most of which are harmless. Certain strains, however, can lead to cancers of the cervix, anus, penis, vulva, vagina, and oropharynx, as well as genital warts. Cervical cancer caused approximately 660,000 new cases and 350,000 deaths worldwide in 2022, according to the World Health Organization.
Addressing Safety Concerns
Although vaccines such as Gardasil and Cervarix have been widely regarded as major public-health advances, they have also faced persistent controversy fueled by misinformation and legal challenges. A recent U.S. court ruling dismissed claims that Gardasil caused long-term health complications, calling the allegations speculative.
The Cochrane analysis found that HPV vaccination is associated only with minor, short-term reactions such as arm soreness. Serious adverse events were rare and occurred at similar rates in vaccinated and unvaccinated groups. The authors said they found no evidence connecting HPV vaccination to the serious side effects frequently discussed on social media.
Implications For Global Vaccination
The findings reinforce global recommendations for routine HPV vaccination of both girls and boys, ideally before age 16 and before sexual activity begins. While the vaccine was initially targeted to girls, an increasing number of countries now also immunize boys to expand community protection.
“Vaccinating boys and girls strengthens population-level immunity,” said Jo Morrison, MD, a gynecologic oncologist and study co-author. She noted that long-term follow-up will clarify the vaccine’s effect on other HPV-related cancers, including those that affect men.
Most existing studies come from high-income countries, highlighting the need for more data from low- and middle-income regions, where the cervical-cancer burden is highest. Researchers expect additional evidence to emerge in the coming decades, as cancers linked to HPV typically take many years to develop.
Related topics
